The PF7+ extends the capabilities of the PF7 to enable it to cope with every stage of biopharmaceutical therapy development.
The PF7+ extends the capabilities of the PF7 to enable it to cope with every stage of biopharmaceutical therapy development.

Watson-Marlow Fluid Technology has introduced the Flexicon PF7+, a peristaltic filling pump which provides a no-waste solution and 21 CFR compliance for critical aseptic final fill applications.

The PF7+ builds on Flexicon's expertise in peristaltic filling to ensure high value products such as ATMPs, vaccines, and cell and gene therapies are protected from contamination and damage to viability.

Bioprocessing needs are becoming increasingly complex with the development of new biological therapies, so adopting smarter technologies for final fill processes is vital. The PF7+ extends the capabilities of the PF7 to enable it to cope with every stage of biopharmaceutical therapy development, from research and development to clinical trials and small batch production.

The new final fill pump offers zero waste start-up and 100% in-process weight checking when connected to a third-party balance, so more liquid can be used for viable product and there is less waste. To ensure accuracy in fill volumes, the PF7+ has dynamic recalibration to automatically adjust if a series of consecutive fills deviates too far from the fill target.